Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.

Clin Cancer Res · 2022 · PMC9377734 · PMID 34862243

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Despite limited data, a clear trend was observed for increases in serum GDF-15 with higher exposure (as measured by AUC last ) of siremadlin for both high-dose regimens (1A/1B) and low-dose regimens (2A/2C; Fig. 2 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.